한국어

Contents

A breakthrough in Spinal Muscular Atrophy Treatment

Successful Clinical Trial Case Studies

As the trends of bioindustry focus on the personalization, customized treatment, the demand for rare disease clinical trials have been also increased. According to the marker research from FMI, CAGR of rare disease clinical trials market(2023~2033) is 9.7%. The grwoth factors of this market are 1) incrased focus on gene therapies 2) grwoing interest in RNA-targeted therapies, increasing collaboration bewteen stake holders.

However, generally, rare disease only affect the small patient population, it's quite challenging to conduct a clinical trial. Today, we will look through the successful clinical trial case of rare disease, spinal muscular atrophy.

Brief explanation of SMA

Spinal Muscular Atrophy (SMA) is a genetic disorder, primarily caused by mutations in the SMN1 (Survival Motor Neuron 1) gene. This gene is essential for producing a protein critical for the survival of motor neurons. This disease is classified into several types based on the age of onset and severity of symptoms.

  1. Type 1 (Severe): Symptoms appear before 6 months of age and it is the most severe form. It involves severe muscle weakness and breathing difficulties.
  2. Type 2 (Intermediate): Symptoms appear between 6 and 18 months of age. Individuals can sit but often cannot walk
  3. Type 3 (Mild): Symptoms appear after 18 months of age. Individuals can walk or stand but experience progressive muscle weakness.
  4. Type 4 (Adult-Onset): Symptoms appear in adulthood and it is the mildest form, with slowly progressing muscle weakness.

Treatment and Management: While there is no cure for SMA, treatments such as Spinraza (nusinersen), gene therapy (Zolgensma), physical therapy, and respiratory support can help alleviate symptoms and improve quality of life. Spinraza is administered via intrathecal injection into the spinal fluid. SMA presents significant challenges for patients and their families, but advances in treatment options are improving outcomes and quality of life for those affected by the condition.

The success factor of Spinraza

The secret of success is amazing effect that Spinrazas. Neverthelss, there were additional factors lead the success of clinical trials.

  1. Mechanism of Action: Spinraza is an antisense oligonucleotide designed to increase the production of fully functional SMN protein by altering the splicing of SMN2 gene transcripts. In SMA patients, the SMN1 gene is missing or mutated, and the SMN2 gene produces a truncated, less functional form of the SMN protein. Spinraza helps convert SMN2 gene transcripts into more functional SMN protein, compensating for the lack of SMN1.

  2. Robust Clinical Trials: The clinical trials for Spinraza, such as the ENDEAR and CHERISH studies, were well-designed with rigorous methodologies. These trials included randomized, double-blind, and sham-controlled phases, which are the gold standard in clinical research. This ensured that the results were reliable and could be attributed to the drug rather than other factors.

  3. Significant Improvement in Motor Function: The trials demonstrated significant improvements in motor function and survival rates among SMA patients treated with Spinraza compared to those who received a placebo. These improvements were measured using standardized scales such as the Hammersmith Infant Neurological Examination (HINE) and the Motor Function Measure (MFM).

  4. Early Intervention: The success of Spinraza was particularly notable in early intervention. Infants and children who received the treatment early in the disease progression showed substantial benefits, including achieving motor milestones that would not typically be reached by untreated patients.

  5. Safety Profile: Spinraza demonstrated a favorable safety profile in clinical trials. While some adverse effects were reported, they were generally manageable and did not outweigh the significant benefits observed in motor function and survival.

  6. Regulatory Support: The success of Spinraza was also facilitated by strong support and fast-track designations from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This expedited the review and approval process, allowing quicker access to the treatment for patients in need.

As such, well-organized clinical design is necessary for fast approval. Huscience, an analytical CRO can provide an advice for analysis process for better result. If you would lilke to conduct a succsssful clinical trials, Please contact us.

Reference


[1]Daroff, R. B., Fenichel, G. M., Jankovic, J., & Mazziotta, J. C. (2012). Bradley's Neurology in Clinical Practice. Elsevier Health Sciences.

[2]Finkel, R. S., Mercuri, E., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., ... & Wang, C. H. (2018). Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements, and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 28(3), 197-207. https://doi.org/10.1016/j.nmd.2017.11.004

[3]Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., ... & Kirschner, J. (2018). Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 28(2), 103-115. https://doi.org/10.1016/j.nmd.2017.11.005

[4]National Institute of Neurological Disorders and Stroke (NINDS). (n.d.). Spinal Muscular Atrophy Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Spinal-Muscular-Atrophy-Fact-Sheet
[5]Genetics Home Reference. (n.d.). Spinal Muscular Atrophy. Retrieved from https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy[6]Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., ... & De Vivo, D. C. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 377(18), 1723-1732. https://doi.org/10.1056/NEJMoa1702752

[7]This reference corresponds to a pivotal clinical trial that demonstrated the efficacy and safety of nusinersen (Spinraza) in patients with infantile-onset spinal muscular atrophy. You can find this study on PubMed by searching for the title or DOI.

[8]Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., ... & De Vivo, D. C. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 377(18), 1723-1732. DOI: 10.1056/NEJMoa1702752

Back to list